Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 19Neoplasm Metastasis 3Neoplasms 2Bulbo-Spinal Atrophy, X-Linked 2Salivary Gland Neoplasms 1Prostatic Neoplasms, Castration-Resistant 1Prostate Cancer Metastatic Disease 1PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy 1Ovarian Neoplasms 1Metastatic Hormone-sensitive Prostate Cancer 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer 1Colorectal Neoplasms 1Castrate Sensitive Prostate Cancer 1Carcinoma, Renal Cell 1Carcinoma, Hepatocellular 1Bites and Stings 1Advanced Solid Tumor 1Adenocarcinoma 1

Interventions

olaparib 3enzalutamide 2darolutamide 2Prednisone 2Prednisolone 2Pluvicto 2Docetaxel 2Androgen Antagonists 2Abiraterone Acetate 2testosterone 17 beta-cypionate 1radium Ra 223 dichloride 1fludarabine phosphate 1fludarabine 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × abiraterone × 90 days × Clear all
NCT07553988 2026-04-28

A Comparative Dose-finding Study of RS-113 in Patients With Metastatic Castration-resistant Prostate Cancer

R-Pharm

Phase 2 Active not recruiting
120 enrolled
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡